JCVI statement on mpox vaccination as a routine programme

Source: DHSC 10.11.23

This statement provides Joint Committee on Vaccination and Immunisation (JCVI) advice on the
Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN) vaccine for the prevention of mpox in terms
of programme cost-effectiveness and likely impact on epidemiology.

Click here to read in full.
Published 10 November 2023